Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019

Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old...

Descripción completa

Detalles Bibliográficos
Autores principales: Ide, Satoshi, Saito, Sho, Akazawa, Tsubasa, Furuya, Takahito, Masuda, Junichi, Nagashima, Maki, Asai, Yusuke, Ogawa, Tatsunori, Yamamoto, Ryohei, Ishioka, Haruhiko, Kanda, Kohei, Okuhama, Ayako, Wakimoto, Yuji, Suzuki, Tetsuya, Akiyama, Yutaro, Miyazato, Yusuke, Nakamura, Keiji, Nakamoto, Takato, Nomoto, Hidetoshi, Moriyama, Yuki, Ota, Masayuki, Morioka, Shinichiro, Matsuda, Wataru, Uemura, Tatsuki, Kobayashi, Kentaro, Sasaki, Ryo, Katagiri, Daisuke, Kutsuna, Satoshi, Hayakawa, Kayoko, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596653/
https://www.ncbi.nlm.nih.gov/pubmed/34804800
http://dx.doi.org/10.1016/j.idcr.2021.e01343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596653/
https://www.ncbi.nlm.nih.gov/pubmed/34804800
http://dx.doi.org/10.1016/j.idcr.2021.e01343

Ejemplares similares